Toxoplasma gondii-associated Guillain-Barre syndrome in an immunocompetent patient

Journal of Clinical Microbiology

Volumn 36, Issue 12, 1998, Pages 3724-3725

  Bossi, Philippe ^a   Caumes, Eric ^a   Paris, Luc ^a   Dardé, Marie Laure ^b   Bricaire, François ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE;

ADULT; ARTICLE; CASE REPORT; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOCOMPETENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

CESTODA; TOXOPLASMA GONDII;

EID: 0031723993     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.12.3724-3725.1998     Document Type: Article

References (5)

1. Dano, P., J. Le Guyader, and R. P. Caron. 1985. Polyradiculonévrite aigüe et toxoplasmose. Rev. Neurol. 141:743-745.
2. Dardé, M. L., I. Villena, J. M. Pinon, and I. Beguinot. 1998. Severe toxoplasmosis caused by a Toxoplasma gondii strain with a new isoenzyme type acquired in French Guyana. J. Clin. Microbiol. 36:324.
3. Hughes, R. A., and J. F. Rees. 1997. Clinical and epidemiologic features of Guillain-Barré syndrome. J. Infect. Dis. 176(Suppl. 2):S92-S98.
4. Rostami, A. M. 1995. Guillain-Barré syndrome: clinical and immunological aspects. Springer Semin. Immunopathol. 17:29-42.
5. Salisbury, D. M. 1998. Association between oral poliovaccine and Guillain-Barré syndrome? Lancet 351:79-80.